Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male

NCT03387553 2026-03-27

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

31 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

4,220 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT07455110 2026-03-27

BR Male

Completed

65 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06422455 2026-03-18

Access to Genetic Testing in Underserved Patients With Cancer

Phase NA Recruiting

800 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00897702 2026-01-28

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Completed

269 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

Adjuvant WIDER

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

ELEGANT

BR Male

Access to Genetic Testing in Underserved Patients With Cancer

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

e3

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer